Controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine, versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Understanding personalised medicine - the e-learning course

p62: Metabolism and the tumour microenvironment

Editor's Choice for April 2016

Targeting AFP in hepatocellular cancer

Patient perspective on immunotherapy and the ITOC-3 conference

Editor's Choice for February 2016

Polycystic kidney disease: Identifying a pathogenic pathway

What does the iManageCancer project hope to achieve?

Cancer-associated thrombosis: Switching patients to warfarin after 6-month completion of anticoagulant treatment

Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis